684 related articles for article (PubMed ID: 28259679)
1. A pH-responsive glycolipid-like nanocarrier for optimising the time-dependent distribution of free chemical drugs in focal cells.
Cheng B; Lu B; Liu X; Meng T; Tan Y; Zhu Y; Liu N; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Apr; 522(1-2):210-221. PubMed ID: 28259679
[TBL] [Abstract][Full Text] [Related]
2. Selective redox-responsive drug release in tumor cells mediated by chitosan based glycolipid-like nanocarrier.
Hu YW; Du YZ; Liu N; Liu X; Meng TT; Cheng BL; He JB; You J; Yuan H; Hu FQ
J Control Release; 2015 May; 206():91-100. PubMed ID: 25796347
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles.
Hu FQ; Liu LN; Du YZ; Yuan H
Biomaterials; 2009 Dec; 30(36):6955-63. PubMed ID: 19782395
[TBL] [Abstract][Full Text] [Related]
4. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy.
Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F
Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168
[TBL] [Abstract][Full Text] [Related]
5. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cytotoxicity of core modified chitosan based polymeric micelles for doxorubicin delivery.
Ye YQ; Chen FY; Wu QA; Hu FQ; Du YZ; Yuan H; Yu HY
J Pharm Sci; 2009 Feb; 98(2):704-12. PubMed ID: 18563810
[TBL] [Abstract][Full Text] [Related]
7. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
[TBL] [Abstract][Full Text] [Related]
8. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin.
Hu FQ; Wu XL; Du YZ; You J; Yuan H
Eur J Pharm Biopharm; 2008 May; 69(1):117-25. PubMed ID: 17997293
[TBL] [Abstract][Full Text] [Related]
9. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
[TBL] [Abstract][Full Text] [Related]
10. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
Hu FQ; Zhang YY; You J; Yuan H; Du YZ
Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
[TBL] [Abstract][Full Text] [Related]
11. Chitosan-tripolyphosphate nanoparticles functionalized with a pH-responsive amphiphile improved the in vitro antineoplastic effects of doxorubicin.
Nogueira-Librelotto DR; Scheeren LE; Vinardell MP; Mitjans M; Rolim CMB
Colloids Surf B Biointerfaces; 2016 Nov; 147():326-335. PubMed ID: 27543694
[TBL] [Abstract][Full Text] [Related]
12. Effect of chitosan based glycolipid-like nanocarrier in prevention of developing acquired drug resistance in tri-cycle treatment of breast cancer.
Meng T; Qiu G; Hong Y; Yuan M; Lu B; Wu J; Yuan H; Hu F
Int J Pharm; 2019 Jan; 555():303-313. PubMed ID: 30471372
[TBL] [Abstract][Full Text] [Related]
13. Chitosan oligosaccharide-arachidic acid-based nanoparticles for anti-cancer drug delivery.
Termsarasab U; Cho HJ; Kim DH; Chong S; Chung SJ; Shim CK; Moon HT; Kim DD
Int J Pharm; 2013 Jan; 441(1-2):373-80. PubMed ID: 23174411
[TBL] [Abstract][Full Text] [Related]
14. Linoleic acid-grafted chitosan oligosaccharide micelles for intracellular drug delivery and reverse drug resistance of tumor cells.
Du YZ; Wang L; Yuan H; Hu FQ
Int J Biol Macromol; 2011 Jan; 48(1):215-22. PubMed ID: 21093477
[TBL] [Abstract][Full Text] [Related]
15. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
18. Improved cytotoxicity and multidrug resistance reversal of chitosan based polymeric micelles encapsulating oxaliplatin.
Xu YY; Du YZ; Yuan H; Liu LN; Niu YP; Hu FQ
J Drug Target; 2011 Jun; 19(5):344-53. PubMed ID: 20854014
[TBL] [Abstract][Full Text] [Related]
19. Simply constructed chitosan nanocarriers with precise spatiotemporal control for efficient intracellular drug delivery.
Kong M; Zuo Y; Wang M; Bai X; Feng C; Chen X
Carbohydr Polym; 2017 Aug; 169():341-350. PubMed ID: 28504154
[TBL] [Abstract][Full Text] [Related]
20. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]